Spectrum of antiphospholipid antibodies (aPL) in patients with cerebrovascular disease

Journal of Stroke and Cerebrovascular Diseases

Volumn 10, Issue 5, 2001, Pages 222-226

  Gonzales Portillo, Fernando ^a   McIntyre, John A ^b   Wagenknecht, Dawn R ^b   Williams, Linda S ^c,d,e   Bruno, Askiel ^c   Biller, José ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b St Francis Hospital   (United States)

^c INDIANA UNIVERSITY   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035675969     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2001.29818     Document Type: Article

References (47)

1. Immunospecificity and mechanism of action of IgG lupus anticoagulants
2. Antiphosphatidylethanolamine (aPE) antibodies: A survey
3. Antiphospholipid-protein antibodies: Laboratory detection and clinical relevance
4. Phospholipid binding plasma proteins required for antiphospholipid antibody detection: An overview
5. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
6. A clinical study of the lupus anticoagulant
7. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events
8. Lupus anticoagulant in acquired immunodeficiency syndrome
9. Antiphospholipid antibodies and cerebral ischemia in young people
10. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia
11. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome
12. Neurological disease associated with antiphospholipid antibodies
13. Antiphospholipid antibodies: Autoantibodies with a difference
14. Antiphospholipid-protein antibodies and ischemic stroke: Not just cardiolipin anymore
15. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 Cases
16. The role of antiphospholipid antibodies in stroke
17. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome
18. Antiphospholipid antibodies
19. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test
20. Obstetric complications associated with the lupus anticoagulant
21. Prevalence and heterogeneity of antiphosphatidylethanolamine (aPE) antibodies in patients with recurrent early pregnancy losses
22. Anticardiolipin antibodies and the lupus anticoagulant
23. The anticardiolipin antibody syndrome
24. Anticardiolipin antibodies are an independent risk factor for ischemic stroke
25. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death
26. The spectrum of neurologic disease associated with antiphospholipid antibodies
27. Cerebral venous thrombosis with lupus anticoagulants
28. Cerebral infarct, TIA, and lupus inhibitor
29. Prospective study of anticardiolipin antibodies in stroke
30. Anticardiolipin antibodies: A study of frequency in TIA and stroke
31. Cerebrovascular ischemic events with high positive anticardiolipin antibodies
32. Elevated antiphosphatidylserine antibodies are a risk factor for ischemic stroke
33. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in SLE
34. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment
35. Antiphospholipid antibodies are a risk factor for early renal allograft failure
36. Henoch-Schönlein Purpura and stroke: Antiphosphatidylethanolamine (aPE) antibody in CSF and serum
37. Antibodies to beta(2)-glycoprotein I in ischemic stroke
38. Lupus anticoagulants: Diagnostic dilemma and clinical challenge
39. Antiphospholipid antibodies (aPL): Risk assessments for solid organ, bone marrow, and tissue transplantation
40. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke
41. The relationship between lupus anticoagulants and antibodies to phospholipid
42. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system
43. Antiphospholipid antibodies in cerebral ischemia
44. Lupus anticoagulants, anticardiolipin antibodies and cerebral ischemia
45. Lupus anticoagulant, anticardiolipin antibodies in young adults with cerebral ischemia
46. Factors which predict antiphospholipid immunoreactivity in young people with focal neurologic events
47. Neurological aspects of antiphospholipid antibody syndrome